AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

by Barry101 | Feb 28, 2025 | Press Release

Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strainsOCALA, Fla., Feb. 28, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Paul Goepfert, MD, of...

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

by Barry101 | Feb 26, 2025 | Press Release

OCALA, Fla., Feb. 26, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that the American has accepted the Company’s...

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

by Barry101 | Feb 26, 2025 | Press Release

OCALA, Fla., Feb. 26, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company’s Board of Directors (the “Board”) has, by unanimous vote, appointed David Chemerow as an...

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

by Barry101 | Feb 25, 2025 | Press Release

Several subjects who received the highest dose in Phase 1 will also be included in Phase 2OCALA, Fla., Feb. 25, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been...

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

by Barry101 | Feb 11, 2025 | Press Release

Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint...